AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
19 C
New York
Friday, October 23, 2026

Tag: candidates

newsFORsourcecompanycontentinformation1releasesmarket

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

Owners In Honor® Awarded SBA Grant to Expand National Business Acquisition Training for Veterans

Funding from the SBA Office of Veterans Business Development will scale Buyers Basecamp through the VBOC networkHOUSTON, Oct. 19, 2026 /PRNewswire/ -- Owners In...

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective...

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe...

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at...

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy...

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 19, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR),...

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 18, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR),...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

Changes to the Board of Directors of H. Lundbeck A/S

Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. Following...

Changes to the Board of Directors of H. Lundbeck A/S

Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. Following...

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®...

AHN Cancer Center Launches RANDY’S Trial, Funded by Community Support and Inspired by a Firefighter’s Legacy

Clinical trial funded through The Randy & Stephanie Meyer Spread Goodness Fund seeks to expand surgical options for patients facing appendix and other peritoneal...

CRISPR Market worth $6.12 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Oct. 16, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the CRISPR Market is projected to reach USD 6.12 billion by 2031 from USD...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCandidates

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers